NAALAD2 and schizophrenia: Moreover, NAALAD2 inhibitors—that elevate synaptic NAAG levels [239]—were found to reduce stereotypical movements in different mouse models (of schizophrenia) [240,241], which further highlights the suitability of NAALAD2 as a novel TD target and the need to conduct further experiments to develop it into an effective TD treatment.